Our results suggest that it may be possible to therapeutically target the NLRP1 inflammasome pathway to increase butyrate-producing commensals in the gut of patients who are otherwise deficient, and thus prevent IBD. The gene discussed is NLRP1; the disease is inflammatory bowel disease.